Moreover, the use of romidepsin, an HDAC inhibitor, or celecoxib, a COX2 inhibitor, reinforces the expression of chemokines such as CXCL9/10 or CCL5 in cancer cells, macrophages and T cells. This evidence concerns the gene CCL5 and cancer.